Egalet Corporation (NASDAQ:EGLT) Files An 8-K Other Events

ME Staff 8-k
-
0

Egalet Corporation (NASDAQ:EGLT) Files An 8-K Other Events
Item 8.01 — Other Events

Equity Offering

On July6, 2017, the Company issued a press release announcing that the Company had priced an offering of its common stock and accompanying warrants. A copy of the press release is attached hereto as Exhibit99.1 and incorporated herein by reference.

Certain Other Financial Information

We had cash, cash equivalents and marketable securities of approximately $87.9million as of June30, 2017. This information is preliminary, has not been reviewed by our independent registered public accounting firm and is subject to the completion of our financial closing process. Our consolidated financial statements as of and for the quarter ended June30, 2017 will be included in our first quarterly report on Form10-Q to be filed with the Securities and Exchange Commission following this offering. Our actual cash and cash equivalents balance may differ from the amounts set forth above as a result of financial adjustments and those changes could be material.

Based on our current cash resources, the proceeds of this offering, expected revenue contributions from our existing approved products, we believe that we will have adequate cash resources to fund our operations into 2019.

Item 9.01 — Financial Statements and Exhibits

(d)Exhibits

Exhibit Number

Description

99.1

Press Release of the Company issued on July6, 2017 announcing the details of the pricing of the offering.


Egalet Corp Exhibit
EX-99.1 2 a17-17039_1ex99d1.htm EX-99.1 Exhibit 99.1     Egalet Announces Pricing of Public Offering of Common Stock and Warrants   Wayne,…
To view the full exhibit click here

About Egalet Corporation (NASDAQ:EGLT)

Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology. The Company’s product SPRIX Nasal Spray, which contains ketorolac tromethamine is a non-steroidal anti-inflammatory drug (NSAID) indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level. The Company’s product OXAYDO is an approved immediate-release (IR) oxycodone product formulated to deter abuse through snorting. The Company’s product candidate, ARYMO ER is an abuse-deterrent (AD), extended-release (ER), oral morphine formulation. The Company’s product candidate, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation.